AQP1 expression combined with β-catenin could be used to re-classify astrocytoma patients into four prognostic groups and patients with AQP1 low/β-catenin low expression had better outcome than others (with either high expression of AQP1 or β-catenin: AQP1 low/β-catenin high, AQP1 high/β-catenin low, and AQP1 high/β-catenin high). The gene discussed is AQP1; the disease is astrocytoma (excluding glioblastoma).